Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates

On November 7, 2024, Aprea Therapeutics, Inc. released its financial results for the third quarter ending September 30, 2024. The company also provided an operational update for the same period. A press release detailing these updates has been issued by the company.

The information provided in the press release and the corporate presentation slide deck, as per the Form 8-K filing, is not considered as “filed” for the purposes of the Securities Exchange Act of 1934. It is also not subject to the liabilities or deemed incorporated by reference into any future filings, except as specifically referenced in such filings.

Additionally, on the same day, Aprea Therapeutics updated its corporate presentation slide deck, outlining its precision oncology approach through synthetic lethality therapeutics. The presentation disclosed the progression of their lead optimization programs, highlighting their macrocyclic ATR inhibitor, APR-1051, ATR inhibitor ATRN-119, and DDR inhibitor.

The ATRN-119 was noted as the first macrocyclic ATR inhibitor, potentially offering enhanced selectivity and tolerability for continuous daily dosing. On the other hand, APR-1051, a WEE1 inhibitor, was emphasized as a promising candidate due to its notable anti-tumor activity and improved safety profile. The company highlighted key milestones and ongoing studies for these potent inhibitors.

Aprea Therapeutics has demonstrated strong drug development expertise in synthetic lethality and targeted therapy. Management, led by President and CEO Oren Gilad, Ph.D., presented an overview of the company’s pipeline, including the phase 1/2a clinical studies of ATRN-119 and APR-1051.

The company’s intellectual property portfolio was described, showcasing issued US patents protecting their lead molecules and analogs, emphasizing innovation in potential cancer treatment.

Financially, as of November 7, 2024, Aprea Therapeutics reported cash and equivalents of approximately $26.2 million. With a focus on achieving critical milestones and exploring strategic partnerships, the company intends to finance operations through the fourth quarter of 2025.

Investors are anticipated to closely monitor upcoming catalysts, including the H1 2025 open-label data for APR-1051 and ATRN-119, and significant progress in dose escalation studies by the end of 2025. Aprea Therapeutics aims to leverage its diversified portfolio and expertise to advance innovative treatments to address unmet medical needs in cancer therapy.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aprea Therapeutics’s 8K filing here.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.